Cytogenetics and in vitro drug resistance of acute leukemia in children and adults;Cytogenetyka i opornos̈ć in vitro na cytostatyki w ostrych białaczkach u dzieci i dorosłych

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 527-537

  Styczyński, Jan ^a   Haus, Olga ^a,b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Acute lymphoblastic leukemia; Acute myeloblastic leukemia; Adults; Children; Cytogenetics; Drug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; CHILD; CHROMOSOME ANALYSIS; CYTOGENETICS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETICS; HUMAN; MULTIDRUG RESISTANCE; REVIEW;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; CYTOGENETIC ANALYSIS; CYTOGENETICS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 39049190343     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Bedi A., Barber J.P., Bedi G.C., el-Deiry W.S., Sidransky D., Vala M.S., Akhtar A.J., Hilton J., Jones R.J.: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood, 1995; 86: 1148-1158
2. Belkov V.M., Krynetski E.Y., Schuetz J.D., Yanishevski Y., Masson E., Mathew S., Raimondi S., Pui C.H., Relling M.V., Evans W.E.: Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood, 1999; 93: 1643-1650
3. Byrd J.C., Dodge R.K., Carroll A., Baer M.R., Edwards C., Stamberg J., Qumsiyeh M., Moore J.O., Mayer R.J., Davey F., Schiffer C.A., Bloomfield C.D.: Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J. Clin. Oncol., 1999; 17: 3767-3775
4. Creutzig U., Ritter J., Zimmermann M., Reinhardt D., Hermann J., Berthold F., Henze G., Jurgens H., Kabisch H., Havers W., Reiter A., Kluba U., Niggli F., Gadner H.: Improved treatment results in highrisk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J. Clin. Oncol., 2001; 19: 2705-2713
5. Den Boer M.L., Pieters R., Veerman A.J.: Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Leukemia, 1998; 12: 1657-1670
6. Dessen P., Knuutila S., Huret J.L.: Chromosome 7. Atlas of Genetics and Cytogenetics in Oncology and Haematology 2002. Http://www. Infobiogen.fr/services/chromcancer/Indexbychrom/idxa-7.html (22.09.2006)
7. Dwilewicz-Trojaczek J.: Bialaczki u doroslych. W: Onkologia kliniczna (Red: Krzakowski M.) Warszawa: Borgis, 2001; 528-555
8. Evans C.A., Owen-Lynch P.J., Whetton A.D., Dive C.: Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res., 1993; 53: 1735-1738
9. Frost B.M., Forestier E., Gustafsson G., Nygren P., Hellebostad M., Jonsson O.G., Kanerva J., Schmiegelow K., Larsson R., Lonnerholm G.: Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood, 2004; 104: 2452-2457
10. Frost B.M., Forestier E., Gustafsson G., Nygren P., Hellebostad M., Jonmundsson G., Kanerva J., Schmiegelow K., Larsson R., Lonnerholm G., Nordic Society for Paediatric Haematology and Oncology: Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia. Leukemia, 2005; 19: 165-169
11. Goldie J.H., Coldman A.J.: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep., 1979; 63: 1727-1733
12. Grimwade D.: The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract. Res. Clin. Haematol., 2001; 14: 497-529
13. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., Wheatley K., Burnett A.K., Goldstone A.H., Medical Research Council Adult Leukemia Working Party: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 2001; 98: 1312-1320
14. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A., Goldstone A.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998; 92: 2322-2333
15. Holleman A., Cheok M.H., Den Boer M.L., Yang W., Veerman A.J., Kazemier K.M., Pei D., Cheng C., Pui C.H., Relling M.V., Janka-Schaub G.E., Pieters R., Evans W.E.: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med., 2004; 351: 533-542
16. Holleman A., Den Boer M.L., Kazemier K.M., Janka-Schaub G.E., Pieters R.: Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood, 2003; 102: 4541-4546
17. Hongo T., Okada S., Inoue N., Yamada S., Yajima S., Watanabe C., Fujii Y., Horikoshi Y.: Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. Int. J. Hematol., 2002; 76: 251-259
18. Hongo T., Yamada S., Yajima S., Watanabe C., Fujii Y., Kawasaki H., Yazaki M., Hanada R., Horikoshi Y.: Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, Lasparaginase, and vincristine in childhood acute lymphoblastic leukemia. Int. J. Hematol., 1999; 70: 268-277
19. Kalwinsky D.K., Raimondi S.C., Schell M.J., Mirro J.Jr., Santana V.M., Behm F., Dahl G.V., Williams D.: Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J. Clin. Oncol., 1990; 8: 75-83
20. Kaspers G.J., Smets L.A., Pieters R., Van Zantwijk C.H., Van Wering E.R., Veerman A.J.: Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood, 1995; 85: 751-756
21. Kumagai M., Manabe A., Pui C.H., Behm F.G., Raimondi S.C., Hancock M.L., Mahmoud H., Crist W.M., Campana D.: Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J. Clin. Invest., 1996; 97: 755-760
22. Kuss B.J., Deeley R.G., Cole S.P., Willman C.L., Kopecky K.J., Wolman S.R., Eyre H.J., Lane S.A., Nancarrow J.K., Whitmore S.A.: Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet, 1994; 343: 1531-1534
23. Leblanc T., Berger R.: Molecular cytogenetics of childhood acute myelogenous leukaemias. Eur. J. Haematol., 1997; 59: 1-13
24. Lindvall C., Furge K., Bjorkholm M., Guo X., Haab B., Blennow E., Nordenskjold M., Teh B.T.: Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. Haematologica, 2004; 89: 1072-1081
25. Ludwig W.D., Rieder H., Bartram C.R., Heinze B., Schwartz S., Gassmann W., Loffler H., Hossfeld D., Heil G., Handt S., Heyll A., Diedrich H., Fischer K., Weiss A., Volkers B., Aydemir U., Fonatsch C., Gokbuget N., Thiel E., Hoelzer D.: Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood, 1998; 92: 1898-1909
26. Mandelli F., Diverio D., Avvisati G., Luciano A., Barbui T., Bernasconi C., Broccia G., Cerri R., Falda M., Fioritoni G., Leoni F., Liso V., Petti M.C., Rodeghiero F., Saglio G., Vegna M.L., Visani G., Jehn U., Willemze R., Muus P., Pelicci P.G., Biondi A., Lo Coco F.: Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood, 1997; 90: 1014-1021
27. Mann G., Reinhardt D., Ritter J., Hermann J., Schmitt K., Gadner H., Creutzig U.: Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann. Hematol., 2001; 80: 417-422
28. Marie J.P., Legrand O.: Drug resistance in acute leukemias. W: Treatment of acute leukemias. New directions for clinical research. (Red: Pui C.H.) Totowa: Humana Press, 2003: 497-505
29. Martinez-Climent J.A., Garcia-Conde J.: Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes. J. Pediatr. Hematol. Oncol., 1999; 21: 91-102
30. Martinez-Climent J.A., Lane N.J., Rubin C.M., Morgan E., Johnstone H.S., Mick R., Murphy S.B., Vardiman J.W., Larson R.A., Le Beau M.M.: Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia, 1995; 9: 95-101
31. Matherly L.H., Taub J.W.: Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leuk. Lymphoma, 1996; 21: 359-368
32. Maung Z.T., Reid M.M., Matheson E., Taylor P.R., Proctor S.J., Hall A.G.: Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Br. J. Haematol., 1995; 91: 93-100
33. Mrozek K., Heerema N.A., Bloomfield C.D.: Cytogenetics in acute leukemia. Blood Rev., 2004; 18: 115-136
34. Mrozek K., Heinonen K., Lawrence D., Carroll A.J., Koduru P.R., Rao K.W., Strout M.P., Hutchison R.E., Moore J.O., Mayer R.J., Schiffer C.A., Bloomfield C.D.: Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: A cancer and leukemia group B study. Blood, 1997; 90: 4532-4538
35. Palle J., Frost B.M., Forestier E., Gustafsson G., Nygren P., Hellebostad M., Jonsson O.G., Kanerva J., Schmiegelow K., Larsson R., Lonnerholm G.: Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br. J. Haematol., 2005; 129: 189-198
36. Pieters R., Den Boer M.L., Durian M., Janka G., Schmiegelow K., Kaspers G.J., van Wering E.R., Veerman A.J.: Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia, 1998; 12: 1344-1348
37. Pieters R., Klumper E., Kaspers G.J., Veerman A.J.: Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit. Rev. Oncol. Hematol., 1997; 25: 11-26
38. Podolak-Dawidziak M., Dus D., Kielbiñski M., Paprocka M., Wojdat E., Lenart K., Szyda A., Haus O., Kuliszkiewicz-Janus M., Prajs I., Kuliczkowski K.: Clinical relevance of multidrug resistance proteins in patients with de novo acute myeloid leukemia. Adv. Clin. Exp. Med., 2005; 14: 1151-1160
39. Pui C.H., Evans W.E.: Acute lymphoblastic leukemia. N. Engl. J. Med., 1998; 339: 605-615
40. Raimondi S.C., Chang M.N., Ravindranath Y., Behm F.G., Gresik M.V., Steuber C.P., Weinstein H.J., Carroll A.J.: Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood, 1999; 94: 3707-3716
41. Raimondi S.C., Pui C.H., Hancock M.L., Behm F.G., Filatov L., Rivera G.K.: Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia, 1996; 10: 213-224
42. Ramakers-van Woerden N.L., Beverloo H.B., Veerman A.J., Camitta B.M., Loonen A.H., Van Wering E.R., Slater R.M., Harbott J., Den Boer M.L., Ludwig W.D., Haas O.A., Janka-Schaub G.E., Pieters R.: In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia, 2004; 18: 521-529
43. Ramakers-van Woerden N.L., Pieters R., Hoelzer D., Slater R.M., Den Boer M.L., Loonen A.H., Harbott J., Janka-Schaub G.E., Ludwig W.D., Ossenkoppele G.J., van Wering E.R., Veerman A.J., Dutch and German Leukemia Study Groups: In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: A report of the Dutch and German Leukemia Study Groups. Med. Pediatr. Oncol., 2002; 38: 379-386
44. Ramakers-van Woerden N.L., Pieters R., Loonen A.H., Hubeek I., van Drunen E., Beverloo H.B., Slater R.M., Harbott J., Seyfarth J., van Wering E.R., Hahlen K., Schmiegelow K., Janka-Schaub G.E., Veerman A.J.: TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood, 2000; 96: 1094-1099
45. Ramakers-van Woerden N.L., Pieters R., Rots M.G., van Zantwijk C.H., Noordhuis P., Beverloo H.B., Peters G.J., van Wering E.R., Camitta B.M., Pui C.H., Relling M.V., Evans W.E., Veerman A.J.: Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. Leukemia, 2002; 16: 949-951
46. Riley L.C., Hann I.M., Wheatley K., Stevens R.F.: Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br. J. Haematol., 1999; 106: 436-444
47. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., Loffler H., Sauerland C.M., Serve H., Buchner T., Haferlach T., Hiddemann W.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 2002; 100: 59-66
48. Schrappe M., Arico M., Harbott J., Biondi A., Zimmermann M., Conter V., Reiter A., Valsecchi M.G., Gadner H., Basso G., Bartram C.R., Lampert F., Riehm H., Masera G.: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood, 1998; 92: 2730-2741
49. Schrappe M., Reiter A., Ludwig W.D., Harbott J., Zimmermann M., Hiddemann W., Niemeyer C., Henze G., Feldges A., Zintl F., Kornhuber B., Ritter J., Welte K., Gadner H., Riehm H.: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALLBFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood, 2000; 95: 3310-3322
50. Shah N.P.: Loss of response to imatinib: mechanisms and management. Hematology (Am. Soc. Hematol. Educ. Program), 2005; 183-187
51. Shurtleff S.A., Buijs A., Behm F.G., Rubnitz J.E., Raimondi S.C., Hancock M.L., Chan G.F., Pui C.H., Grosveld G., Downing J.R.: TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia, 1995; 9: 1985-1989
52. Silverman L.B., McLean T.W., Gelber R.D., Donnelly M.J., Gilliland D.G., Tarbell N.J., Sallan S.E.: Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer, 1997; 80: 2285-2295
53. Stevens R.F., Hann I.M., Wheatley K., Gray R.G.: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br. J. Haematol., 1998; 101: 130-140
54. Styczynski J., Koltan A., Haus O., Wysocki M.: Differential chemosensitivity in a child with congenital relapsing acute lymphoblastic leukemia. Pediatr. Hematol. Oncol., 2002; 19: 355-360
55. Styczynski J., Pieters R., Huismans D.R., Schuurhuis G.J., Wysocki M., Veerman A.J.: In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br. J. Haematol., 2000; 110: 813-818
56. Styczynski J., Wysocki M.: Differences in significance of drug resistance mechanisms between adult and childhood acute lymphoblastic leukemia. Haematologia, 2002; 32: 313-325
57. Styczynski J., Wysocki M.: In vitro drug resistance profiles of adult acute lymphoblastic leukemia: possible explanation for difference in outcome to similar therapeutic regimens. Leuk. Lymphoma, 2002; 43: 301-307
58. Styczynski J., Wysocki M.: Mechanisms of drug resistance in acute leukemias: therapeutic problem. Adv. Clin. Exp. Med., 2000; 9: 153-161
59. Synold T.W., Relling M.V., Boyett J.M., Rivera G.K., Sandlund J.T., Mahmoud H., Crist W.M., Pui C.H., Evans W.E.: Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest., 1994; 94: 1996-2001
60. Szczepanski T., van der Velden V.H., van Dongen J.J.: Classification systems for acute and chronic leukaemias. Best Pract. Res. Clin. Haematol., 2003; 16: 561-582
61. Tallman M.S., Gilliland D.G., Rowe J.M.: Drug therapy for acute myeloid leukemia. Blood, 2005; 106: 1154-1163
62. Taub J.W., Ge Y.: Down syndrome, drug metabolism and chromosome 21. Pediatr. Blood Cancer, 2005; 44: 33-39
63. Taub J.W., Huang X., Matherly L.H., Stout M.L., Buck S.A., Massey G.V., Becton D.L., Chang M.N., Weinstein H.J., Ravindranath Y.: Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 1999; 94: 1393-1400
64. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., Wermke M., Bornhauser M., Ritter M., Neubauer A., Ehninger G., Illmer T.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 2002; 99: 4326-4335
65. Tosi P., Visani G., Ottaviani E., Testoni N., Pellacani A., Tura S.: Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. Eur. J. Haematol., 1998; 60: 161-165
66. Trueworthy R., Shuster J., Look T., Crist W., Borowitz M., Carroll A., Frankel L., Harris M., Wagner H., Haggard M.: Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. J. Clin. Oncol., 1992; 10: 606-613
67. Uckun F.M., Kersey J.H., Gajl-Peczalska K.J., Heerema N.A., Provisor A.J., Haag D., Gilchrist G., Song C.W., Arthur D.C., Roloff J.: Heterogeneity of cultured leukemic lymphoid progenitor cells from B cell precursor acute lymphoblastic leukemia (ALL) patients. J. Clin. Invest., 1987; 80: 639-646
68. Whitehead V.M., Vuchich M.J., Cooley L.D., Lauer S.J., Mahoney D.H., Shuster J.J., Payment C., Koch P.A., Akabutu J.J., Bowen T., Kamen B.A., Ravindranath Y., Emami A., Look A.T., Beardsley G.P., Pullen D.J., Camitta B.: Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Leuk. Lymphoma, 1998; 31: 507-519
69. Woods W.G., Neudorf S., Gold S., Sanders J., Buckley J.D., Barnard D.R., Dusenbery K., DeSwarte J., Arthur D.C., Lange B.J., Kobrinsky N.L., Children's Cancer Group: A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood, 2001; 197: 56-62
70. Zatonski W., Didkowska J.: Epidemiologia nowotworów złos̈liwych. W: Onkologia kliniczna (Red: Krzakowski M.) Warszawa: Borgis, 2001; 22-50
71. Zhang Y., Lu J., Van den Berghe J., Lee S.H.: Increased incidence of spontaneous apoptosis in the bone marrow of hyperdiploid childhood acute lymphoblastic leukemia. Exp. Hematol., 2002; 30: 333-339
72. Zwaan C.M., Kaspers G.J., Pieters R., Hahlen K., Huismans D.R., Zimmermann M., Harbott J., Slater R.M., Creutzig U., Veerman A.J.: Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood, 2002; 100: 3352-3360
73. Zwaan C.M., Kaspers G.J., Pieters R., Hahlen K., Janka-Schaub G.E., van Zantwijk C.H., Huismans D.R., de Vries E., Rots M.G., Peters G.J., Jansen G., Creutzig U., Veerman A.J.: Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood, 2002; 99: 245-251
74. Zwaan C.M., Meshinchi S., Radich J.P., Veerman A.J., Huismans D.R., Munske L., Podleschny M., Hahlen K., Pieters R., Zimmermann M., Reinhardt D., Harbott J., Creutzig U., Kaspers G.J., Griesinger F.: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 2003; 102: 2387-2394